Men syndrome
Reading File
Finding Sources
Searching PubMed
"multiple endocrine neoplasia" MEN syndrome
Reading File
Reading File
Reading File
Reading File
Here is a thorough overview of Multiple Endocrine Neoplasia (MEN) syndromes based on authoritative medical textbooks:
Multiple Endocrine Neoplasia (MEN) Syndromes
MEN syndromes are a group of autosomal dominant inherited disorders causing proliferative lesions (hyperplasias, adenomas, and carcinomas) in multiple endocrine organs. They share several features that distinguish them from sporadic endocrine tumors:
- Tumors occur at a younger age
- They arise in multiple organs, either simultaneously (synchronously) or at different times (metachronously)
- Within a single organ, tumors are often multifocal
- They are typically preceded by an asymptomatic hyperplastic stage
- They are generally more aggressive and have higher recurrence rates
MEN-1 (Werner Syndrome)
Prevalence: ~2 per 100,000
Gene: MEN1 tumor suppressor gene - encodes a protein called menin, a component of transcription factor complexes. Loss of menin function causes uncontrolled transcriptional activity and neoplasia.
Classic triad - the "3 Ps":
| Organ | Manifestation | Details |
|---|---|---|
| Parathyroid | Primary hyperparathyroidism | Most common manifestation (80%-95%); presents as hyperplasias and adenomas; nearly universal by age 40-50 |
| Pancreas | Pancreatic endocrine tumors | Leading cause of death in MEN-1; often functional; Zollinger-Ellison syndrome (gastrinoma) and hypoglycemia (insulinoma) are most common |
| Pituitary | Anterior pituitary adenoma | Most commonly prolactinoma (macroadenoma); acromegaly can occur with somatotropin-secreting tumors |
Additional features: Duodenal gastrinomas (most common site for gastrinomas in MEN-1), carcinoid tumors, thyroid and adrenocortical adenomas, and lipomas are more frequent than in the general population.
Key note: The duodenum is the most common site of gastrinomas in MEN-1, not the pancreas.
MEN-2A (Sipple Syndrome)
Gene: Germline gain-of-function mutations in the RET proto-oncogene (encodes a receptor tyrosine kinase that binds glial-derived neurotrophic factor)
| Organ | Manifestation | Frequency |
|---|---|---|
| Thyroid (C-cells) | Medullary thyroid carcinoma (MTC) | ~100% of untreated patients; multifocal; often in first two decades of life |
| Adrenal medulla | Pheochromocytoma | 40%-50%; often bilateral; may be extra-adrenal; <10% malignant |
| Parathyroid | Hyperplasia/hypercalcemia | 10%-20%; renal stones may occur |
Variant - Familial Medullary Thyroid Carcinoma (FMTC): Germline RET mutations with isolated MTC, without pheochromocytoma or hyperparathyroidism; tends to be less aggressive and presents at an older age.
MEN-2B (also called MEN-3)
Gene: A single missense point mutation in RET (distinct from MEN-2A mutations), affecting the tyrosine kinase domain, causing constitutive RET activation.
| Feature | Details |
|---|---|
| Medullary thyroid carcinoma | Present; multifocal and more aggressive than in MEN-2A |
| Pheochromocytoma | Present |
| Primary hyperparathyroidism | Absent (key distinguishing feature from MEN-2A) |
| Mucosal/cutaneous neuromas | Ganglioneuromas of lips, tongue, GI tract, skin, eyes, respiratory tract |
| Marfanoid habitus | Long axial skeletal features, hyperextensible joints |
MEN-4
A newer entity that phenocopies MEN-1 clinically, but caused by germline inactivating mutations in CDKN1B, leading to reduced levels of the cell-cycle checkpoint protein p27 (a cyclin-dependent kinase inhibitor).
MEN-5 (Newly Described)
Caused by germline mutations in the MAX tumor suppressor gene. Patients often develop bilateral pheochromocytomas and other tumors. Unlike MEN-2, medullary thyroid carcinoma and C-cell hyperplasia are not seen.
Genetics & Screening Summary
| Syndrome | Gene | Mutation Type | Key Organ |
|---|---|---|---|
| MEN-1 | MEN1 | Loss-of-function (TSG) | Parathyroid > Pancreas > Pituitary |
| MEN-2A | RET | Gain-of-function | Thyroid (MTC), Adrenal, Parathyroid |
| MEN-2B / MEN-3 | RET | Gain-of-function (single missense) | Thyroid (MTC), Adrenal, Neuromas |
| MEN-4 | CDKN1B | Loss-of-function (TSG) | Mimics MEN-1 |
| MEN-5 | MAX | Loss-of-function (TSG) | Bilateral Pheochromocytoma |
Important clinical implication for MEN-2: All patients with medullary thyroid carcinoma - including apparently sporadic cases - should undergo germline RET mutation testing. Carriers are advised to have prophylactic thyroidectomy to prevent the inevitable development of medullary carcinomas (since MTC occurs in virtually 100% of untreated individuals).
In contrast to MEN-1, the benefit of early diagnosis via genetic screening is clearly established in MEN-2 given the life-threatening, preventable nature of MTC.
Sources: Robbins & Kumar Basic Pathology; Robbins, Cotran & Kumar Pathologic Basis of Disease
Can you create a table containing etiopathogenesis, clinical features, management , complications and any other extra relevant points for all types of men syndrome. Make a single table
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
I now have comprehensive data from multiple authoritative surgical and pathology textbooks. Here is the complete single table:
MEN Syndromes - Comprehensive Comparison Table
| Feature | MEN-1 (Werner Syndrome) | MEN-2A (Sipple Syndrome) | MEN-2B (MEN-3) | MEN-4 |
|---|---|---|---|---|
| Inheritance | Autosomal dominant | Autosomal dominant | Autosomal dominant; ~50% arise as de novo mutations | Autosomal dominant |
| Gene Mutated | MEN1 (tumor suppressor gene) on chromosome 11q13 | RET proto-oncogene on chromosome 10q11 | RET proto-oncogene on chromosome 10q11 | CDKN1B (tumor suppressor gene) |
| Protein Affected | Menin - component of transcription factor complexes; loss leads to uncontrolled transcription | RET receptor tyrosine kinase (binds GDNF); gain-of-function = constitutive activation | RET receptor tyrosine kinase - single missense point mutation in tyrosine kinase domain | p27 (Kip1) - cyclin-dependent kinase inhibitor; arrests cell cycle at G1/S; binds CDK4 |
| Type of Mutation | Loss-of-function (TSG - two-hit model: inherited first hit + somatic second hit) | Gain-of-function (missense mutations, mainly exons 10/11) | Gain-of-function (single amino acid substitution, codon 918 of tyrosine kinase domain) | Loss-of-function (TSG - inactivating mutation) |
| Mechanism | Loss of menin disrupts histone methylation and transcriptional regulation, promoting neoplasia in susceptible tissues | Constitutive RET activation drives unchecked growth/differentiation signaling in C-cells and chromaffin cells | Constitutive RET activation (distinct from MEN-2A mutations) - more potent activation, explaining greater aggressiveness | Loss of p27 allows unphosphorylated retinoblastoma protein (Rb) to be phosphorylated by CDK4/cyclin complexes, allowing unchecked cell cycle progression |
| Organs Involved | 3 Ps: Parathyroid, Pancreas (islet cells), Pituitary | Thyroid (C-cells), Adrenal medulla, Parathyroid | Thyroid (C-cells), Adrenal medulla, Peripheral/mucosal nervous system | Parathyroid, Pituitary, Pancreas (NETs) - mimics MEN-1 |
| Typical Age of Onset | 3rd-4th decade; complete penetrance by 40-50 yrs | 2nd-3rd decade | Earlier than MEN-2A, often in childhood/infancy | 5th decade (mean); generally presents later and milder than MEN-1 |
| Parathyroid | Primary hyperparathyroidism in 80%-95% (most common and often first manifestation); multiglandular hyperplasia and adenomas; usually symptomatic via urinary tract (renal stones) rather than bone disease | Parathyroid hyperplasia in 10%-20%; often multiglandular chief cell hyperplasia; usually asymptomatic; nephrolithiasis occasionally | Absent (key distinguishing feature from MEN-2A) | PHPT in >90% (first manifestation); diffuse parathyroid hyperplasia |
| Pancreatic/GI Tumors | Leading cause of death in MEN-1; multifocal islet cell NETs throughout pancreas; often functional: - Gastrinoma (most common functional tumor; usually in duodenal wall submucosa) - Insulinoma (2nd most common) - VIPoma, glucagonoma (less common) - Pancreatic polypeptidoma (most common secreted product overall) | Not a feature | Not a feature | NETs in ~20% (less frequent than MEN-1); gastrinoma is most common functional NET type |
| Thyroid | Not a primary feature (thyroid adenomas occur at slightly increased frequency) | Medullary thyroid carcinoma (MTC) in virtually 100% of untreated patients; multifocal; bilateral; C-cell hyperplasia precedes; arises 1st-2nd decade; relatively indolent course | MTC in virtually 100%; multifocal, bilateral; more aggressive than MEN-2A; arises even earlier (infancy/childhood) | Not a feature |
| Pituitary | Pituitary adenomas in 15%-50%; most commonly prolactinoma (macroadenoma); acromegaly from GH-secreting tumor; rarely ACTH-secreting (Cushing's) | Not a feature | Not a feature | Pituitary adenomas in ~40%; ACTH-secreting adenoma more common (40% of pituitary tumors vs 5% in MEN-1); prolactinoma also occurs |
| Adrenal | Adrenocortical adenomas (benign, non-functional; management conservative) | Pheochromocytoma in 40%-50%; usually bilateral (~80%); benign (<10% malignant); adrenal medullary hyperplasia precedes | Pheochromocytoma; similar frequency to MEN-2A; bilateral; benign | Not a primary feature |
| Extra-endocrine Features | Lipomas (visceral, pleural, retroperitoneal); carcinoid tumors (thymic, bronchial, gastric); cutaneous angiofibromas; collagenomas | None beyond endocrine organs | Mucosal/cutaneous neuromas (tongue, lips, eyelids, pharynx); marfanoid habitus (long axial bones, hyperextensible joints, pectus excavatum, kyphosis, pes planus, scoliosis, congenital hip dislocation); ganglioneuromatosis of GI tract (submucosal/myenteric plexus); thick lips; hypertrophied corneal nerves (slit-lamp); constipation/megacolon picture; diffuse autonomic hypertrophy | None beyond endocrine organs |
| Key Clinical Presentations | - Hypercalcemia (fatigue, polyuria, renal stones) - Peptic ulcer disease / ZES (recurrent, severe) - Secretory diarrhea - Hypoglycemia (sweating, confusion, syncope) - Galactorrhea/amenorrhea (prolactinoma) - Acromegaly | - Neck mass (MTC) - Hoarseness, dysphagia - Hypertension (episodic or sustained) - Pounding headaches, diaphoresis, palpitations (pheo) - Renal stones (hyperparathyroidism) - Diarrhea (calcitonin excess) | - Neck mass (MTC) - Mucosal neuromas on tongue/lips (often first sign in newborns) - Marfanoid body habitus - Pheochromocytoma symptoms - GI symptoms (constipation, dysmotility) | - Hypercalcemia (renal stones, fatigue) - Peptic ulcer / secretory diarrhea (gastrinoma) - Cushing's disease or acromegaly (pituitary) |
| Biochemical Markers | - Elevated PTH + hypercalcemia - Elevated fasting serum gastrin (>1000 pg/mL in ZES); secretin stimulation test - Fasting hypoglycemia + elevated insulin (insulinoma) - Elevated prolactin or IGF-1 | - Elevated calcitonin (basal and pentagastrin/calcium-stimulated) - Elevated plasma metanephrines (pheochromocytoma) - PTH + calcium (parathyroid) | - Elevated calcitonin - Elevated plasma metanephrines - RET mutation on genetic testing | - PTH + calcium - Fasting gastrin - Prolactin, IGF-1, ACTH (pituitary screen) |
| Management - Parathyroid | Subtotal parathyroidectomy (preferred) or total parathyroidectomy with autograft; no truly curative option due to multifocal nature and metachronous recurrence | Total parathyroidectomy + heterotopic autotransplantation in hypercalcemic patients; in normocalcemic patients found with enlarged glands during thyroidectomy - remove only enlarged glands | Not applicable (no hyperparathyroidism) | Follow MEN-1 guidelines; parathyroidectomy for symptomatic hypercalcemia |
| Management - Pancreas / GI | - Gastrinoma: PPIs/H2 blockers (often high dose); surgical resection if isolated; nonsurgical approach generally preferred in MEN-1 due to multifocality - Insulinoma: surgical resection (enucleation or distal pancreatectomy); preop localization by CT + arterial calcium stimulation test - Nonfunctional NETs: watchful waiting if small; surgery for >2 cm or growing lesions - Somatostatin receptor scintigraphy for staging | Not applicable | Not applicable | Same principles as MEN-1; management guidelines not yet standardized (MEN-1 guidelines adopted) |
| Management - Thyroid (MTC) | Not applicable (no MTC) | - Prophylactic thyroidectomy for all RET mutation carriers (timing based on mutation risk category) - Total thyroidectomy + central lymph node dissection - Postop: lifelong calcitonin monitoring - Vandetanib or cabozantinib for metastatic/unresectable MTC - Surgical reoperation for persistently elevated calcitonin | - Urgent prophylactic thyroidectomy in infancy (before age 6 months) due to aggressiveness - Total thyroidectomy + central neck dissection - Postoperative calcitonin monitoring | Not applicable |
| Management - Pheochromocytoma | Not applicable | - Pheochromocytoma MUST be resected before thyroidectomy - Alpha-blockade (phenoxybenzamine) preoperatively - Laparoscopic adrenalectomy preferred; bilateral adrenalectomy for bilateral disease - Unilateral disease: remove affected gland only (avoids Addisonian crisis); ~30% develop contralateral tumor | Same as MEN-2A; urgent management given aggressiveness | Not applicable |
| Management - Pituitary | Prolactinoma: dopamine agonists (cabergoline, bromocriptine); surgery (transsphenoidal) if drug-resistant; GH-secreting: surgery ± octreotide/lanreotide | Not applicable | Not applicable | Similar to MEN-1 pituitary management |
| Screening / Surveillance | - Annual biochemistry: calcium, PTH, fasting gastrin, insulin, prolactin, IGF-1 - Imaging: MRI pituitary, CT/MRI abdomen - Genetic testing of all first-degree relatives - Start screening from age 5-10 yrs in carriers | - Germline RET testing in all patients with MTC (including sporadic cases) - Annual calcitonin + plasma metanephrines in carriers - Prophylactic thyroidectomy timing by mutation risk category - 6-monthly or annual plasma metanephrines post-adrenalectomy | - RET genetic testing - Early thyroidectomy before 6 months of age - Annual plasma metanephrines - Slit-lamp for corneal nerve hypertrophy | - If MEN-1 mutation negative, do next-generation sequencing for CDKN1B - Follow modified MEN-1 surveillance protocols - No consensus guidelines yet |
| Complications | - Metastatic pancreatic NETs (leading cause of death ~45% of MEN-1 deaths) - Malignant carcinoid tumors - Nephrolithiasis / nephrocalcinosis from hypercalcemia - Peptic ulcer complications (perforation, bleeding) - Hypoglycemic coma (insulinoma) - Hypopituitarism / visual field defects (macroadenoma) | - Metastatic MTC (main determinant of prognosis; indolent in MEN-2A) - Hypertensive crisis from pheochromocytoma (fatal if unrecognized pre-operatively) - Renal stones from hyperparathyroidism - Addisonian crisis post bilateral adrenalectomy | - Most aggressive form of MEN - Metastatic MTC (more aggressive than MEN-2A; early death if not treated in infancy) - Hypertensive crisis from pheochromocytoma - GI dysmotility / pseudo-obstruction (ganglioneuromatosis) - Skeletal deformity complications | - Metastatic NETs - Hypercalcemia complications - Cushing's disease complications (if ACTH adenoma) |
| Prognosis | Determined by malignant NETs and carcinoid tumors; hyperparathyroidism itself rarely fatal; ~45% of deaths MEN-1 related; islet cell malignancy is leading killer | MTC course is often indolent; survival can be prolonged even with metastatic disease; pheochromocytoma rarely malignant (<10%) | Worst prognosis of all MEN types; MTC arises earlier and is more aggressive; patients may succumb at a young age; kindred size typically small due to early deaths | Generally favorable; mild and late presentation; prognosis data limited (~80 cases reported in literature) |
| Key Distinguishing Points | - "3 Ps" mnemonic - Duodenum is #1 site for gastrinomas (not pancreas) - TSG mutation (loss-of-function) - Pancreatic NETs are the killer | - Pheo must be ruled out BEFORE thyroid surgery - Parathyroid involved (unlike MEN-2B) - RET gain-of-function | - No hyperparathyroidism (unlike MEN-2A) - Mucosal neuromas + marfanoid habitus are pathognomonic - Most aggressive MEN - Often new (de novo) mutation - Also called MEN-3 | - Phenocopies MEN-1 clinically - Older age at presentation - ACTH adenoma more common than prolactinoma (vs MEN-1) - NETs less frequent - No established guidelines |
Sources: Robbins & Kumar Basic Pathology; Robbins, Cotran & Kumar Pathologic Basis of Disease; Mulholland & Greenfield's Surgery 7e; Sabiston Textbook of Surgery; Harrison's Principles of Internal Medicine 22e
All little smaller table delete the management part
MEN Syndromes - Comparison Table
| Feature | MEN-1 (Werner Syndrome) | MEN-2A (Sipple Syndrome) | MEN-2B (MEN-3) | MEN-4 |
|---|---|---|---|---|
| Inheritance | Autosomal dominant | Autosomal dominant | Autosomal dominant; ~50% de novo mutations | Autosomal dominant |
| Gene | MEN1 (TSG) - chr 11q13 | RET proto-oncogene - chr 10q11 | RET proto-oncogene - chr 10q11 | CDKN1B (TSG) |
| Protein | Menin - transcription factor complex component | RET receptor tyrosine kinase (binds GDNF) | RET receptor tyrosine kinase | p27 (Kip1) - CDK inhibitor |
| Mutation Type | Loss-of-function (two-hit model) | Gain-of-function (exons 10/11) | Gain-of-function (codon 918, tyrosine kinase domain) | Loss-of-function |
| Mechanism | Loss of menin → deregulated transcription → neoplasia | Constitutive RET activation → unchecked growth signaling | Constitutive RET activation (more potent than MEN-2A) | Loss of p27 → Rb phosphorylation uninhibited → unchecked cell cycle |
| Organs Involved | Parathyroid, Pancreas, Pituitary (3 Ps) | Thyroid (C-cells), Adrenal medulla, Parathyroid | Thyroid (C-cells), Adrenal medulla, Peripheral nervous system | Parathyroid, Pituitary, Pancreas (mimics MEN-1) |
| Age of Onset | 3rd-4th decade | 2nd-3rd decade | Childhood/infancy (earliest of all) | 5th decade (latest; milder) |
| Parathyroid | 80%-95% (first and most common manifestation); hyperplasia + adenomas; renal stones > bone disease | 10%-20%; multiglandular chief cell hyperplasia; usually asymptomatic | Absent (key difference from MEN-2A) | >90% (first manifestation); diffuse hyperplasia |
| Pancreas / GI | Leading cause of death; multifocal NETs - Gastrinoma (most common; duodenal wall) - Insulinoma (2nd most common) - VIPoma, glucagonoma (rare) | Not a feature | Not a feature | NETs in ~20%; gastrinoma most common type |
| Thyroid | Not a primary feature | MTC in ~100% of untreated patients; multifocal; bilateral; C-cell hyperplasia precedes; relatively indolent | MTC in ~100%; multifocal; bilateral; more aggressive than MEN-2A | Not a feature |
| Pituitary | 15%-50%; prolactinoma (most common); acromegaly (GH-secreting); rarely Cushing's | Not a feature | Not a feature | ~40%; ACTH-secreting adenoma more common (vs prolactinoma in MEN-1) |
| Adrenal | Adrenocortical adenomas (benign, non-functional) | Pheochromocytoma 40%-50%; bilateral in ~80%; benign (<10% malignant); adrenal medullary hyperplasia precedes | Pheochromocytoma; bilateral; benign; similar frequency to MEN-2A | Not a feature |
| Extra-endocrine Features | Lipomas; carcinoid tumors (thymic, bronchial); cutaneous angiofibromas; collagenomas | None | Mucosal neuromas (tongue, lips, eyelids); marfanoid habitus; ganglioneuromatosis of GI tract; thick lips; hypertrophied corneal nerves; constipation/megacolon picture; skeletal deformities (pectus, kyphosis, pes planus) | None |
| Key Clinical Features | Hypercalcemia; recurrent peptic ulcers (ZES); secretory diarrhea; hypoglycemia (insulinoma); galactorrhea/amenorrhea; acromegaly | Neck mass; hoarseness; episodic hypertension; headaches + diaphoresis + palpitations (pheo); renal stones; diarrhea (calcitonin excess) | Neck mass; mucosal neuromas on tongue/lips (often 1st sign in newborns); marfanoid habitus; pheo symptoms; GI dysmotility | Hypercalcemia; peptic ulcers; Cushing's disease or acromegaly |
| Key Biochemical Markers | Elevated PTH + Ca²⁺; fasting gastrin >1000 pg/mL; secretin stimulation test; fasting hypoglycemia + elevated insulin; elevated prolactin / IGF-1 | Elevated calcitonin (basal + stimulated); elevated plasma metanephrines; PTH + Ca²⁺ | Elevated calcitonin; elevated plasma metanephrines; RET mutation on genetic testing | PTH + Ca²⁺; fasting gastrin; prolactin; ACTH; IGF-1 |
| Screening | Annual Ca²⁺, PTH, gastrin, insulin, prolactin, IGF-1; MRI pituitary; CT/MRI abdomen; genetic testing of relatives from age 5-10 yrs | RET testing in all MTC patients (including sporadic); prophylactic thyroidectomy timing by mutation risk; annual calcitonin + metanephrines | RET genetic testing; thyroidectomy before 6 months of age; annual metanephrines; slit-lamp for corneal nerves | Next-gen sequencing for CDKN1B if MEN-1 negative; modified MEN-1 protocols (no consensus guidelines) |
| Complications | Metastatic pancreatic NETs (leading cause of death); nephrolithiasis; peptic ulcer bleeding/perforation; hypoglycemic coma; hypopituitarism; visual field defects | Metastatic MTC; hypertensive crisis from unrecognized pheochromocytoma; renal stones; Addisonian crisis post bilateral adrenalectomy | Metastatic MTC (early death if untreated); hypertensive crisis; GI pseudo-obstruction; skeletal deformities | Metastatic NETs; hypercalcemia complications; Cushing's disease sequelae |
| Prognosis | ~45% of deaths MEN-1 related; malignant NETs/carcinoids are the killers; hyperparathyroidism rarely fatal | Often indolent; prolonged survival even with metastatic MTC; pheo rarely malignant | Worst prognosis; most aggressive MEN; early death possible; small kindred size due to early mortality | Generally favorable; late and mild presentation; very rare (~80 cases in literature) |
| Key Distinguishing Points | - "3 Ps" mnemonic - Duodenum is #1 site for gastrinomas - TSG / loss-of-function - Pancreatic NETs are the killer | - Pheo MUST be excluded before thyroid surgery - Parathyroid involved (unlike MEN-2B) - RET gain-of-function | - No hyperparathyroidism - Mucosal neuromas + marfanoid habitus are pathognomonic - Most aggressive - De novo mutations common | - Phenocopies MEN-1 clinically - ACTH adenoma > prolactinoma - NETs less frequent - No established guidelines |
Sources: Robbins & Kumar Basic Pathology; Robbins, Cotran & Kumar Pathologic Basis of Disease; Mulholland & Greenfield's Surgery 7e; Sabiston Textbook of Surgery; Harrison's Principles of Internal Medicine 22e
Make it understandable by ug students
MEN Syndromes - Quick Reference for UG Students
Remember: All MEN syndromes are autosomal dominant, tumors are multifocal, occur at a younger age, and are more aggressive than sporadic tumors.
| Feature | MEN-1 | MEN-2A | MEN-2B | MEN-4 |
|---|---|---|---|---|
| Other Name | Werner Syndrome | Sipple Syndrome | Also called MEN-3 | - |
| Gene | MEN1 gene | RET gene | RET gene (different spot) | CDKN1B gene |
| Simple Explanation of Defect | "Brake" on cell growth is lost → uncontrolled growth | "Accelerator" of cell growth is stuck ON → uncontrolled growth | Same accelerator stuck ON, but harder than MEN-2A | Another "brake" is lost → looks like MEN-1 |
| Easy Mnemonic | 3 Ps - Parathyroid, Pancreas, Pituitary | Thyroid + Adrenal + Parathyroid | Thyroid + Adrenal + Neuromas (no parathyroid!) | Mimics MEN-1 |
| Parathyroid | ✅ Most common feature (80-95%); first to appear; causes high calcium → kidney stones | ✅ Mild, only 10-20% | ❌ ABSENT (important exam point!) | ✅ Most common feature (>90%); first to appear |
| Pancreas | ✅ Most dangerous; causes death - Gastrinoma → severe stomach ulcers (Zollinger-Ellison) - Insulinoma → low blood sugar attacks | ❌ Not involved | ❌ Not involved | ✅ Mild (only 20%); gastrinoma most common |
| Thyroid | ❌ Not involved | ✅ Medullary thyroid cancer in nearly 100%; appears in teens-20s; relatively slow | ✅ Medullary thyroid cancer in nearly 100%; appears in infancy/childhood; very aggressive | ❌ Not involved |
| Pituitary | ✅ 15-50%; usually prolactinoma (causes milk discharge, missed periods); rarely acromegaly | ❌ Not involved | ❌ Not involved | ✅ ~40%; ACTH-secreting tumor (causes Cushing's) more common here |
| Adrenal | ✅ Benign, harmless adrenal nodules | ✅ Pheochromocytoma (40-50%); usually both sides; causes high BP + headache + sweating | ✅ Pheochromocytoma; similar to MEN-2A | ❌ Not involved |
| Unique / Extra Features | Skin lipomas, carcinoid tumors, skin tags (angiofibromas) | Nothing extra beyond the 3 glands | ⭐ Lumps on tongue/lips (mucosal neuromas); Marfan-like body (tall, long limbs, flexible joints); GI constipation | Nothing extra |
| What Patient Looks Like | Middle-aged adult with kidney stones + stomach ulcers + hormonal issues | Young adult with neck lump + high BP episodes | Child/teen with bumps on tongue, thin body, Marfan appearance + neck lump | Middle-aged adult similar to MEN-1 |
| Most Important Blood Tests | High calcium; high gastrin; low blood sugar; high prolactin | High calcitonin; high plasma metanephrines | High calcitonin; high metanephrines | High calcium; high gastrin; high ACTH |
| Most Dangerous Complication | Spread of pancreatic tumors to liver = #1 cause of death | Medullary thyroid cancer spread | Medullary thyroid cancer (very aggressive, can kill in young age) | Spread of pancreatic tumors |
| Most Important Exam Point | Duodenum (not pancreas) is the #1 site for gastrinoma | Pheo must be operated on FIRST before thyroid surgery (or patient may die from BP crisis) | No parathyroid disease + mucosal neuromas = MEN-2B | Clinically same as MEN-1 but gene is different |
| Prognosis | Moderate; pancreatic cancers are the killers | Good; thyroid cancer is often slow | Worst of all; most aggressive; early death possible | Best; mildest and latest presentation |
Simple "What's Different" Summary
| MEN-1 vs MEN-2A | MEN-2A vs MEN-2B | |
|---|---|---|
| Key difference | MEN-1 has pancreas + pituitary; MEN-2A does NOT | MEN-2B has no parathyroid but has neuromas + marfanoid body |
| Gene | MEN-1 = MEN1 gene (brake); MEN-2A = RET gene (accelerator) | Both MEN-2A and 2B use RET gene, but different mutations |
Exam Favorites ⭐
- MEN-1 = 3 Ps (Parathyroid + Pancreas + Pituitary) → gene = MEN1 → protein = Menin
- MEN-2A = Medullary thyroid cancer + Pheo + Parathyroid → gene = RET
- MEN-2B = Medullary thyroid cancer + Pheo + Neuromas + Marfanoid (NO parathyroid) → gene = RET
- MEN-4 = Looks like MEN-1 → gene = CDKN1B → protein = p27
- In MEN-2, always check for pheo before operating on the thyroid
- MEN-2B is the most aggressive and the only one with physical deformities visible on the face/body
This is a shared conversation. Sign in to Orris to start your own chat.